A Mechanistic Pharmacokinetic/Pharmacodynamic Model for Sequence-Dependent Synergy in Pemetrexed–Osimertinib Combinations Against Non-Small Cell Lung Cancer (NSCLC): Translational Insights

<b>Background and Objectives:</b> Combining osimertinib (OSI) with pemetrexed (PEM) can enhance antitumor efficacy; however, the benefit is schedule-dependent. Our previous pharmacodynamic (PD) study showed that concurrent PEM + OSI is limited by OSI-induced G1 arrest, attenuating early PEM cytotoxi...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kuan Hu, Yan Lin, Huachun Ji, Tong Yuan, Yu Xia, Jin Yang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-03-01
Edice:	Pharmaceutics
Témata:	pemetrexed osimertinib synergy effect schedule-dependent pharmacokinetic/pharmacodynamic (PK/PD) modeling
On-line přístup:	https://www.mdpi.com/1999-4923/18/4/408
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!